ClinicalTrials.gg
CompletedNCT06162169Updated Apr 4, 2025

A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

A Phase 1 interventional study of JAB-21822 and Itraconazole in Healthy Subjects, sponsored by Allist Pharmaceuticals, Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Allist Pharmaceuticals, Inc. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a phase I study to evaluate drug-drug interactions (DDIs) of JAB-21822 as a perpetrator combined with midazolam , rosuvastatin, and digoxin and to evaluate DDIs of JAB-21822 as a victim combined with itraconazole, rifampicin, and omeprazole in healthy subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Allist Pharmaceuticals, Inc. is the lead sponsor of 25 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ;Healthy subjects aged 18 to 50 years (including both ends) at the time of signing
  2. Male subjects weighed ≥50kg, female subjects weighed ≥45kg, (BMI) was between 19.0 and 26.0kg/m2, BMI= weight (kg)/height 2 (m2), including boundary values.
  3. Subjects voluntarily signed written informed consent and were able to communicate well with the investigator

Exclusion criteria

Exclusion Criteria:

  1. History of severe systemic diseases, history of liver and kidney insufficiency, history of mental illness, history of drug dependence;
  2. Patients with a history of interstitial pneumonia, pulmonary fibrosis or other interstitial lung diseases who were not eligible for admission by the investigators;
  3. Have a history of dysphagia or any gastrointestinal disease that affects drug absorption, and have digestive diseases (such as peptic ulcer, pancreatitis, colitis, etc.) within 3 months before the first dose;
  4. The investigator believes that the subject has any other circumstances that make him or her unfit to participate in this clinical trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    JAB-21822+Itraconazole

    Drug: JAB-21822 · Drug: Itraconazole

  • Experimental
    JAB-21822+ Rifampicin

    Drug: JAB-21822 · Drug: Rifampicin

  • Experimental
    JAB-21822+ Omeprazole

    Drug: JAB-21822 · Drug: Omeprazole

  • Experimental
    Dazolam , Rosuvastatin calcium and digoxin with JAB-21822

    Drug: JAB-21822 · Drug: Midazolam , Rosuvastatin calcium and digoxin

Interventions

  • JAB-21822 was administered orally

  • DrugItraconazole

    Itraconazole was administered orally

  • DrugOmeprazole

    Omeprazole was administered orally

  • DrugMidazolam , Rosuvastatin calcium and digoxin

    Midazolam , Rosuvastatin calcium and digoxin was administered orally

  • DrugRifampicin

    Rifampicin was administered orally

06

What researchers measure

Primary outcomes

  1. Observed maximum concentrations (Cmax )of JAB-21822

    Time frame: approximately 10 days

  2. Area under the concentration versus time curve from dose to the last quantifiable concentration (AUC0-t) of JAB-21822

    Time frame: approximately 10 days

  3. Area under the concentration versus time curve from dose to infinity (AUC0-∞) of JAB-21822

    Time frame: approximately 10 days

  4. Observed maximum concentrations (Cmax )of midazolam, rosuvastatin, and digoxin

    Time frame: approximately 10 days

  5. Area under the concentration versus time curve from dose to the last quantifiable concentration (AUC0-t) of midazolam, rosuvastatin, and digoxin

    Time frame: approximately 10 days

  6. Area under the concentration versus time curve from dose to infinity (AUC0-∞) of midazolam, rosuvastatin, and digoxin

    Time frame: approximately 10 days

07

Study locations

1 site
  • Beijing GoBroad Hospital
    Beijing, Beijing 102206, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Feb 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2023
First posted
Dec 8, 2023
StartActual
Nov 25, 2023
Primary completionActual
Feb 20, 2024
CompletionActual
Feb 20, 2024
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06162169
Responsible party
Sponsor
First posted
Dec 8, 2023
Start date
Nov 25, 2023
Primary completion
Feb 20, 2024
Completion
Feb 20, 2024
Last update
Apr 4, 2025

Study contacts

He Qing B.Pharm
principal investigator · Beijing Gaobo Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glecirasib

Start the discussion